![Henrik Stage](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Henrik Stage
Geen lopende functies
Profiel
Henrik Stage is the founder of Skape Bio ApS, founded in 2025, holding the title of Director.
Mr. Stage was the founder of ADCendo ApS, founded in 2017, holding the title of Chief Financial Officer from 2021 to 2022.
Stage is also the founder of Fuse Vectors ApS..
Mr. Stage is currently Chairman at Biomia ApS since 2022.
Stage is currently Director at ResoTher Pharma AS.
Stage is currently Director at iNotify ApS.
Stage is currently Partner at Ventac Partners A. Mr. Stage is currently Owner at Next Stage Ventures ApS.
Formerly, Mr. Stage was Chief Executive Officer at RICC A from 2012 to 2014.
Stage was Chief Financial Officer at SynAct Pharma AB from 2016 to 2022.
Stage was Chief Financial Officer at RhoVac AB. Stage completed graduate education at Copenhagen Business School.
Actieve functies van Henrik Stage
| Bedrijven | Functie | Begin |
|---|---|---|
Ventac Partners A/S
 Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Provides life science consulting services | Corporate Officer/Principal | - |
ResoTher Pharma AS
 ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Directeur/Bestuurslid | - |
Next Stage Ventures ApS
 Next Stage Ventures ApS Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products | Corporate Officer/Principal | - |
Eerdere bekende functies van Henrik Stage
| Bedrijven | Functie | Einde |
|---|---|---|
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Algemeen Directeur | 07-07-2021 |
| SYNACT PHARMA AB | Financieel Directeur/CFO | 07-01-2022 |
| CHOSA ONCOLOGY AB | Financieel Directeur/CFO | - |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Algemeen Directeur | 09-01-2014 |
Opleiding van Henrik Stage
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
5
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Copenhagen Business School
 Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Health Technology |
SynAct Pharma AB
 SynAct Pharma AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs for treatment inflammatory diseases | Health Technology |
Ventac Partners A/S
Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Provides life science consulting services | Commercial Services |
RhoVac AB
 RhoVac AB BiotechnologyHealth Technology Engages in the research and development of immunotherapy for therapeutic cancer vaccines | Health Technology |
Next Stage Ventures ApS
Next Stage Ventures ApS Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products | Commercial Services |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Health Technology |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Health Technology |
